TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02470871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eptacog alfa (activated) or pdFVII
Description: Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.~Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eptacog alfa (activated) or pdFVII
Description: Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.~Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL689
Description: Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL689
Description: Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)
Study: NCT00965991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
Study: NCT01667952

Intervention type: GENETIC
Intervention: Family History Questionnaire (FHQ)
Description: Consented subjects will be given the Family History Questionnaire (FHQ) to complete either in clinic or at home. Subjects who chose to complete the FHQ at home will be given a stamped envelope with a label. For participants who are children and cannot fill out the questionnaire on their own, the clinic RSA will instruct the parent, guardian, or legally authorized representative (LAR) present to fill out the questionnaire, reminding them that the You in the questionnaire refers to their child.

Intervention type: GENETIC
Intervention: Salvia sample
Description: The saliva samples will be collected in Oragene DNA Self-Collection Kits or a similar product. Patients will be instructed to donate about 2ml of saliva into a vial, which contains 2ml of product. Oragene or similar solution.

Intervention type: OTHER
Intervention: Blood sample
Description: Subjects will be offered the option of a blood collection instead of saliva. For adult subjects who opt for blood collection, two tubes of blood (approximately 20cc) will be drawn from the utilizing a sterile technique. For subjects under the age of 18 who opt for blood collection, approximately 3-5cc of blood will be collected utilizing a sterile technique.
Study: NCT01838889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted psychological intervention (Positive Health Programme)
Description: This study will evaluate the efficacy of a group psychological intervention (PHP) based on the principles of Cognitive Behaviour Therapy in treating depression in postpartum women.
Study: NCT04448080

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)
Description: Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)
Description: Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma
Study: NCT02732145

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Three Rings Vulvoscopy (TRIV)
Description: Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Three Rings Vulvoscopy (TRIV)
Description: Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Three Rings Vulvoscopy (TRIV)
Description: Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Three Rings Vulvoscopy (TRIV)
Description: Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Histopathology
Description: Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Histopathology
Description: Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Histopathology
Description: Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Histopathology
Description: Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.
Study: NCT00851136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO95780
Description: Intravenous repeating dose
Study: NCT03482674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIMINI lifestyle intervention
Description: DIMINI lifestyle intervention consists of the DIMINI-kit which contains health information, a list of food recommendations with additional information on calories, serving size and weight (traffic light rating system), a nutrition and an exercise diary. Participants in the intervention group can choose between a paper-based version or an app-based version of the DIMINI-kit. In addition, the kit includes an elastic exercise band with exercise poster, a measuring tape for self-control of the waist size and a pedometer.
Study: NCT04565314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy'Mum
Description: Mothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months.
Study: NCT01702428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix
Description: Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix
Description: Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix
Description: Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
Study: NCT02564822

Intervention type: PROCEDURE
Intervention: Visual Stimulation
Description: volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.

Intervention type: PROCEDURE
Intervention: Visual Stimulation
Description: volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
Study: NCT04599816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan at a dose of 3 mcg/kg
Description: levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan at a dose of 6 mcg/kg
Description: levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan at a dose of 12 mcg/kg
Description: levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction
Study: NCT01702428

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
Study: NCT01188018

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice (BA)
Description: Participants in this arm will receive a single session of brief advice. A counselor will briefly discuss the risks associated with smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Subjects will receive 4 counseling sessions (over 18 weeks) in which their thoughts about their smoking will be discussed. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone(weeks 6 and 18).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HE)
Description: Subjects will receive 4 counseling sessions (over 18 weeks)in which they will receive educational information about the risks of smoking and the benefits of quitting. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone (weeks 6 and 18).
Study: NCT01300286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiaSTAP
Description: One time dose of 70 mg/kg will be administered intravenously.
Study: NCT03690414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental BHVI2
Description: Experimental BHVI2 eye drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate 0.02% eye drops
Description: Atropine eye drops

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination eye drops
Description: Combination eye drops with experimental BHVI2 plus 0.02% atropine
Study: NCT03453749

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Salovum
Description: Salovum is freeze dried egg yolk, highly enriched with anti-secretory factor. Salovum is registered as a medical food by the EU
Study: NCT06316661

Intervention type: DIAGNOSTIC_TEST
Intervention: stress perfusion cardiac magnetic resonance
Description: stress perfusion cardiac magnetic resonance according to guidelines, with quantitative evaluation for microvascular dysfunction assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: stress perfusion cardiac magnetic resonance
Description: stress perfusion cardiac magnetic resonance according to guidelines, with quantitative evaluation for microvascular dysfunction assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise test
Description: bike exercise with ECG and non invasive respiratory gas exchange monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise test
Description: bike exercise with ECG and non invasive respiratory gas exchange monitoring
Study: NCT00447954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501 implant
Description: High Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501 implant
Description: Low Dose

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Sham Procedure
Study: NCT00795626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic education in the reduction of the risk estimate to cardiovascular events
Description: Systematic education during 4 assessment throughout one year
Study: NCT02599467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ULNT 1 and EMG recording
Description: While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ULNT 1 and EMG recording
Description: While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ULNT 1 and EMG recording
Description: While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
Study: NCT02589093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation
Study: NCT00521586

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13 valent pneumococcal conjugate vaccine
Description: TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
Study: NCT01702428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
Study: NCT00521586

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13 valent pneumococcal conjugate vaccine
Description: TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
Study: NCT01702428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
Study: NCT00778063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 2 mcg/kg intranasally 30 minutes prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
Study: NCT00763932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
Study: NCT02027363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation
Study: NCT02640651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC-Stimulator (PLUS version)
Description: transcranial direct current stimulation
Study: NCT00936494

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cold ablation inferior turbinate reduction
Description: The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
Study: NCT01300559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissuelink device
Description: Tissuelink device plus Unipolar electrocautery
Study: NCT04006366

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Time restricted feeding
Description: We propose a pilot and feasibility trial of a 10 hour time restricted eating intervention among post-bariatric surgery patients.
Study: NCT00980109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active oseltamivir
Description: Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zanamivir for inhalation
Description: Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for inhalation
Description: Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
Study: NCT04004793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Description: Participants were will be asked to follow a weight management programme, in accordance with the American Diabetes Association guidelines. Weight loss will be induced with a diet replacement phase using an energy restriction diet (energy deficit by 500\~750 kcal/day) for 3 months, with \<35% as fat, \>15% as protein. The minimum energy intake is 1200kcal/day for men and 1000kcal/day for women.. Additionally, participants were encouraged to increase physical exercise (≥150 minutes of brisk walking every week or ≥10000 steps per day).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive lifestyle intervention
Description: Participants were will be asked to follow a weight management programme, in accordance with the American Diabetes Association guidelines. Weight loss will be induced with a diet replacement phase using an energy restriction diet (energy deficit by 500\~750 kcal/day) for 3 months, with \<35% as fat, \>15% as protein. The minimum energy intake is 1200kcal/day for men and 1000kcal/day for women.. Additionally, participants were encouraged to increase physical exercise (≥150 minutes of brisk walking every week or ≥10000 steps per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG Oral Tablet
Description: The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
Study: NCT02071563

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CSB14

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RUSF1

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SC+